Unclaimed brand
Arecor is a clinical-stage biotech company, developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#1B3F91
Jacksons Purple
27, 63, 145
222, 69, 34
81, 57, 0, 43
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
Arecor Therapeutics plc is a cutting-edge pharmaceutical company dedicated to transforming patient care and advancing existing therapeutic medicines. With a strong focus on enhancing treatments, they strive to bring safer, more effective, and convenient solutions to patients. Using their proprietary Arestat™ technology platform, Arecor develops enhanced medicines for a wide range of chronic conditions, particularly diabetes.
Their portfolio includes innovative products such as AT247, an ultra-rapid acting insulin, and AT278, an ultra-concentrated ultra-rapid acting insulin. Additionally, Arecor offers a specialized Tetris Pharma Portfolio, which focuses on registering, marketing, and distributing commercial-stage specialty hospital products across the UK and Europe. The company also collaborates with leading pharmaceutical and biotechnology companies to enhance their proprietary products through technology partnerships.
Arecor's commitment to innovation and patient care is evident in their continuous efforts to improve the effectiveness and convenience of therapies. Stay up to date with Arecor's latest advancements in the industry through their news and events section. For those interested in joining their team, Arecor offers career opportunities.
For more information, visit their website or contact them directly
Company type
Public Company
Year founded
2007
Company size
11-50 employees
Arestat protein formulation technology
Ultra-concentrated rapid-acting insulin
Automated insulin delivery therapeutics
Oral peptide drug delivery
Cardiometabolic biotechnology
